As on Wednesday, Inozyme Pharma Inc (NASDAQ: INZY) started slowly as it slid -0.71% to $2.80, before settling in for the price of $2.82 at the close. Taking a more long-term approach, INZY posted a 52-week range of $2.38-$7.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 0.00% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -35.73%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -16.63%. This publicly-traded company’s shares outstanding now amounts to $64.18 million, simultaneously with a float of $43.99 million. The organization now has a market capitalization sitting at $179.87 million. At the time of writing, stock’s 50-day Moving Average stood at $3.21, while the 200-day Moving Average is $4.62.
Inozyme Pharma Inc (INZY) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Inozyme Pharma Inc’s current insider ownership accounts for 31.52%, in contrast to 65.09% institutional ownership. According to the most recent insider trade that took place on Apr 02 ’24, this organization’s CEO sold 7,523 shares at the rate of 6.94, making the entire transaction reach 52,210 in total value, affecting insider ownership by 20,665.
Inozyme Pharma Inc (INZY) Earnings and Revenue Records
Inozyme Pharma Inc’s EPS decrease for this current 12-month fiscal period is -16.63% and is forecasted to reach -1.58 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 13.10% through the next 5 years, which can be compared against the -35.73% growth it accomplished over the previous five years trading on the market.
Inozyme Pharma Inc (NASDAQ: INZY) Trading Performance Indicators
Let’s observe the current performance indicators for Inozyme Pharma Inc (INZY). It’s Quick Ratio in the last reported quarter now stands at 7.68. The Stock has managed to achieve an average true range (ATR) of 0.24.
In the same vein, INZY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.55, a figure that is expected to reach -0.41 in the next quarter, and analysts are predicting that it will be -1.58 at the market close of one year from today.
Technical Analysis of Inozyme Pharma Inc (INZY)
Through scrutinizing the latest numbers posted by the [Inozyme Pharma Inc, INZY], it can be observed that its last 5-days Average volume of 0.53 million was better the volume of 0.53 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 33.21% While, its Average True Range was 0.24.
Raw Stochastic average of Inozyme Pharma Inc (INZY) in the period of the previous 100 days is set at 10.77%, which indicates a major fall in contrast to 29.63% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 66.31% that was higher than 61.43% volatility it exhibited in the past 100-days period.
